Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Atara Biorapeutics

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Where Atara Biotherapeutics Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1% over the last 24 hours, at $5.00 per share.

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Atara Biotherapeutics Earnings Preview

Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.98.

inkl

Read news from The Economist, FT, and more,
with one subscription

Atara Biotherapeutics Earnings Perspective: Return On Capital Employed

Atara Biotherapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Atara Biotherapeutics (NASDAQ:ATRA) reported Q4 sales of $7.55 million. Earnings fell to a loss of $93.35 million, resulting in a 10.26% decrease from last quarter.

Preview: Atara Biotherapeutics's Earnings

Preview: Atara Biotherapeutics's Earnings

Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.69.

1

Organisations

Maxar Technologies

Palantir Technologies

SherwinWilliams

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play